Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Oncopeptides AB to Discuss Withdrawal of Pepaxto and Refocus on R&D - Conference Call Transcript

Oct 22, 2021 / 02:30PM GMT
Release Date Price: kr4.52 (-78.03%)
Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Good afternoon, and good morning to everyone joining us. It's a somber day here at Oncopeptides. Today, we talk about the withdrawal of PEPAXTO from the U.S. market and the refocus of the company back to a research and development organization. On Slide 2, we list our disclaimers and look for you to consult our filings for more detailed information.

Slide 3. I'm joined on the call today by a couple of other executives, Dr. Jakob Lindberg, our Chief Scientific Officer; and Dr. Klaas Bakker, our Chief Medical Officer, who will be available to help during the Q&A period.

Next slide. So the key takeaway messages from the press release that we sent out just a short time ago is that we've reached agreement with the FDA to withdraw PEPAXTO from the U.S. market. So we're in the process of working closely with the agency regarding patients that are currently on the drug, both clinically and commercially, to ensure an appropriate transition and/or continuation of therapy. So this decision was reached in advance of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot